Guidelines     MGP Ltd



Forthcoming guidance
 
Published guidance
 
Select guidance type:
Select Clinical speciality:

Date: from to

Search



Title Type Clinical speciality   Published date   Review Date
Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib NICE Technology Appraisal Cancer Mar 2019 -
Pertuzumab for adjuvant treatment of early HER2-positive breast cancer NICE Technology Appraisal Cancer Mar 2019 -
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum–based chemotherapy (terminated appraisal) NICE Technology Appraisal Cancer Mar 2019 -
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) NICE Technology Appraisal Musculoskeletal and joints Mar 2019 -
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies NICE Technology Appraisal Cancer Mar 2019 -
Cochlear implants for children and adults with severe to profound deafness NICE Technology Appraisal Eye, ear, nose and throat Mar 2019 -
ciclosporin (Verkazia®) All Wales Medicines Strategy Group appraisal Eye, ear, nose and throat Mar 2019 -
romiplostim (Nplate®) All Wales Medicines Strategy Group appraisal Haematological conditions Mar 2019 -
Benralizumab for treating severe eosinophilic asthma NICE Technology Appraisal Respiratory Mar 2019 -
Intrapartum care for women with existing medical conditions or obstetric complications and their babies NICE Clinical Guideline Women's health Mar 2019 -
Air pollution: outdoor air quality and health NICE Quality Standard Public health Feb 2019 -
People's experience using adult social care services NICE Quality Standard Public health Feb 2019 -
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia NICE Technology Appraisal Cancer Feb 2019 -
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer NICE Technology Appraisal Cancer Feb 2019 -
Encorafenib with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma NICE Technology Appraisal Cancer Feb 2019 -
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) NICE Evidence summary Pain Feb 2019 -
Child abuse and neglect NICE Quality Standard Paediatrics Feb 2019 -
Serious eye disorders NICE Quality Standard Eye, ear, nose and throat Feb 2019 -
Sexual health NICE Quality Standard Sexual health Feb 2019 -
Delirium: prevention, diagnosis and management NICE Clinical Guideline Neurology Feb 2019 -
Antenatal care for uncomplicated pregnancies NICE Clinical Guideline Women's health Feb 2019 -
Cough (acute): antimicrobial prescribing NICE Clinical Guideline Respiratory Feb 2019 -
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease NICE Technology Appraisal Cancer Jan 2019 -
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies NICE Technology Appraisal Cancer Jan 2019 -
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer NICE Technology Appraisal Cancer Jan 2019 -
Darvadstrocel for treating perianal fistula in Crohn's disease NICE Technology Appraisal Gastrointestinal Jan 2019 -
Regorafenib for previously treated advanced hepatocellular carcinoma NICE Technology Appraisal Cancer Jan 2019 -
Renal and ureteric stones: assessment and management NICE Clinical Guideline Renal conditions Jan 2019 -
Cerebral palsy in adults NICE Clinical Guideline Neurology Jan 2019 -
Children and young people exposed prenatally to alcohol SIGN guidance Paediatrics Jan 2019 -
Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare) Independent professional body guideline Sexual health Jan 2019 -
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years NICE Technology Appraisal Cancer Dec 2018 -
dolutegravir/rilpivirine (Juluca®) All Wales Medicines Strategy Group appraisal Infection Dec 2018 -
brivaracetam (Briviact®) All Wales Medicines Strategy Group appraisal Neurology Dec 2018 -
Pembrolizumab for adjuvant treatment of melanoma with high risk of recurrence NICE Technology Appraisal Cancer Dec 2018 -
Pancreatic cancer NICE Quality Standard Cancer Dec 2018 -
Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma NICE Technology Appraisal Cancer Dec 2018 -
Liposomal cytarabine and daunorubicin for untreated acute myeloid leukaemia NICE Technology Appraisal Cancer Dec 2018 -
Vandetanib for treating medullary thyroid cancer NICE Technology Appraisal Cancer Dec 2018 -
Oesophago-gastric cancer NICE Quality Standard Cancer Dec 2018 -